# Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA

> **NCT07532408** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 43 (estimated)

## Conditions studied

- Aplastic Anemia

## Interventions

- **DRUG:** Romiplostim N01

## Key facts

- **NCT ID:** NCT07532408
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07532408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07532408, "Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07532408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*